stockportfolio.pro
Haemonetics Corporation (HAE)
Healthcare · Medical Devices · NYSE
Haemonetics Corporation revenue & earnings — last 10 fiscal years
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $886.12M | $903.92M | $967.58M | $988.48M | $870.46M | $993.20M | $1.17B | $1.31B | $1.36B | $1.33B |
| Gross profit | $378.49M | $411.91M | $417.54M | $484.51M | $397.84M | $505.50M | $615.10M | $691.55M | $748.96M | $787.59M |
| Net income | $-26.27M | $45.57M | $55.02M | $76.53M | $79.47M | $43.38M | $115.40M | $117.56M | $167.68M | $97.31M |
| Net margin | -3.0% | 5.0% | 5.7% | 7.7% | 9.1% | 4.4% | 9.9% | 9.0% | 12.3% | 7.3% |
Source: Haemonetics Corporation SEC filings (10-K). 18 years of history available in the interactive view.
Explore 18 years of Haemonetics Corporation financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track HAE in your portfolio →
About Haemonetics Corporation
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries;vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions. It sells its products through direct sales force and independent distributors. The company was founded in 1971 and is headquartered in Boston, Massachusetts.
Haemonetics Corporation — frequently asked questions
What is Haemonetics Corporation's revenue?
Haemonetics Corporation (HAE) reported revenue of $1.33B for fiscal year 2026, down 2.0% from the prior year, according to its SEC filings.
Is Haemonetics Corporation profitable?
Yes. HAE earned net income of $97.31M in fiscal 2026, a net margin of 7.3%.
What is HAE's P/E ratio?
Haemonetics Corporation trades at a price-to-earnings ratio of about 38.4 based on the latest data in our nightly-refreshed cache.
How fast is Haemonetics Corporation growing?
HAE's revenue grew at roughly 8.9% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
Where does this data come from?
All figures are computed from Haemonetics Corporation's official SEC filings (10-K and 10-Q), covering 18 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.